Biodesix announces the launch of its genestrat ngs™ test and the iqlung™ testing strategy with unprecedented time to results

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today the national launch of its new genestrat ngs™ genomic test, a blood-based tumor profiling test. the 52-gene panel includes guideline recommended mutations to help physicians treating advanced- stage lung cancer patients identify targeted therapy mutations, such as egfr, alk, kras, met, ntrk, erbb2, and others, and delivers them in an ex
BDSX Ratings Summary
BDSX Quant Ranking